- Home
- MTUS vs CELC Comparison
MTUS vs CELC Comparison
Compare MTUS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTUS
- CELC
- Stock Information
- Founded
- MTUS 1899
- CELC 2011
- Country
- MTUS United States
- CELC United States
- Employees
- MTUS N/A
- CELC N/A
- Industry
- MTUS
- CELC Medical Specialities
- Sector
- MTUS
- CELC Health Care
- Exchange
- MTUS NYSE
- CELC Nasdaq
- Market Cap
- MTUS 546.3M
- CELC 440.0M
- IPO Year
- MTUS N/A
- CELC 2017
- Fundamental
- Price
- MTUS $16.57
- CELC $13.79
- Analyst Decision
- MTUS
- CELC Strong Buy
- Analyst Count
- MTUS 0
- CELC 6
- Target Price
- MTUS N/A
- CELC $30.67
- AVG Volume (30 Days)
- MTUS 424.7K
- CELC 204.8K
- Earning Date
- MTUS 08-07-2025
- CELC 08-13-2025
- Dividend Yield
- MTUS N/A
- CELC N/A
- EPS Growth
- MTUS N/A
- CELC N/A
- EPS
- MTUS N/A
- CELC N/A
- Revenue
- MTUS $1,042,900,000.00
- CELC N/A
- Revenue This Year
- MTUS $8.76
- CELC N/A
- Revenue Next Year
- MTUS $8.74
- CELC N/A
- P/E Ratio
- MTUS N/A
- CELC N/A
- Revenue Growth
- MTUS N/A
- CELC N/A
- 52 Week Low
- MTUS $10.78
- CELC $7.58
- 52 Week High
- MTUS $23.26
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- MTUS 75.43
- CELC 65.10
- Support Level
- MTUS $15.21
- CELC $12.48
- Resistance Level
- MTUS $16.59
- CELC $13.60
- Average True Range (ATR)
- MTUS 0.45
- CELC 0.77
- MACD
- MTUS 0.18
- CELC 0.10
- Stochastic Oscillator
- MTUS 98.00
- CELC 93.32
About MTUS METALLUS INC
Metallus Inc is an America-based manufacturer of alloy steel, as well as carbon and micro-alloy steel. The portfolio of the company includes special bar quality steel, seamless mechanical tubes, and value-add solutions, such as precision steel components. The company also supplies machining and thermal treatment services and manages raw material recycling programs that work as a feeder system for its melt operations. The company's products and services are used in the following sectors: oil and gas; automotive; industrial equipment; mining; construction; rail; aerospace and defense; heavy truck; agriculture and power generation. Geographically, the company mainly serves customers in the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.